---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-192484"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2023-07-25T23:59:59+00:00"
generated_at: "2026-06-13T03:17:29.918720+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics CFO Brian Silver resigns; CEO MacBeath appointed interim CFO, Dworak as Principal Accounting Officer

## Summary
- Brian Silver resigned as CFO, effective July 21, 2023; CEO Gavin MacBeath named interim Principal Financial Officer.
- Leiden Dworak appointed Principal Accounting Officer, effective July 21, 2023; previously VP, Finance since April 2022.
- Dworak's base salary increased to $340,000; target bonus raised to 35% from 30%; granted 25,000 stock options at $2.23.
- Stock options vest over four years (25% one-year cliff, then monthly). No family relationships or related party transactions.

## SEC filing metadata
- accession: 0001193125-23-192484
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2023-07-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312523192484/0001193125-23-192484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312523192484/d845896d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-192484
- JSON: https://secwatch.observer/filing/0001193125-23-192484.json
- Plain text: https://secwatch.observer/filing/0001193125-23-192484.txt

## Key facts
- Executive change
  Brian Silver resigned as Chief Financial Officer at TScan Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: replacing Brian Silver, who had previously announced his resignation as Chief Financial Officer of the Company effective July 21, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312523192484/0001193125-23-192484-index.htm
- Executive change
  Leiden Dworak was appointed as Principal Accounting Officer at TScan Therapeutics, Inc..
  - Action: appointed
  - Role: Principal Accounting Officer
  source text: appointed Leiden Dworak as Principal Accounting Officer of the Company, effective July 21, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312523192484/0001193125-23-192484-index.htm
- Executive change
  Gavin MacBeath was appointed as interim Principal Financial Officer at TScan Therapeutics, Inc..
  - Action: appointed
  - Role: interim Principal Financial Officer
  source text: appointed Gavin MacBeath, Ph.D., as the interim Principal Financial Officer of the Company, effective July 21, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312523192484/0001193125-23-192484-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.